Drug eluting stents have become an important component in percutaneous treatment of patients with symptomatic coronary artery disease. There are limited data to evaluate effectiveness and safety of drug eluting stents in atrial fibrillation patients. In this study, everolimus eluting stent (XIENCE V) implantations and follow up results in patients with atrial fibrillation patinets were evaluated. 60 AF patients who underwent everolimus eluting stent deployment for coronary artery lesions in Hacettepe University Faculty of Medicine Department of Cardiology included. Baseline demographic, clinic and angiographic data, procedure related complications and outcomes during follow up were studied. The prevalence of CVA, thyroid dysfunction, heart valve disease, COPD and systolic dysfunction evaluated by echocardiography were more frequent than patients with sinus rhythm. As primary endpoints all-cause mortality was %3,3 and target lesion failure was %1,7. As secondary outcomes target vessel revascularization, myocardial infarction and major adverse cardiovascular events were seen %1,7, %1,7 and %6,7 respectively. There are no cardiac mortality, TLR and stent thrombosis cases. For all outcomes, there are no significant differences between patients with AF and sinus rhythm. Moreover, procedure related complication rate was same between the two groups. These results demonstrate effectiveness and safety of the XIENCE V everolimus eluting stent in patients with AF.